Chemotherapy Induced Peripheral Neuropathy clinical trials

Explore recruiting chemotherapy induced peripheral neuropathy clinical trials.

Recruiting chemotherapy induced peripheral neuropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chemotherapy Induced Peripheral Neuropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2a Safety and Efficacy study of TAR-0520 gel in prevention of taxanes-induced peripheral neuropathy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric open-label study (CAPNEUCHIM)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effectiveness and cost-effectiveness of Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial.

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Soothing Pain After ChEmotherapy: Psilocybin As INtervention (SPACE-PAIN) — a randomized controlled pilot trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Effectiveness and cost-effectiveness of ozone treatment in patients with paresthesia (numbness, tingling) secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial (OzoParQT).

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Chemotherapy Induced Peripheral Neuropathy trials by city

Chemotherapy Induced Peripheral Neuropathy in Toronto Chemotherapy Induced Peripheral Neuropathy in Vancouver Chemotherapy Induced Peripheral Neuropathy in Montreal Chemotherapy Induced Peripheral Neuropathy in Calgary Chemotherapy Induced Peripheral Neuropathy in Edmonton Chemotherapy Induced Peripheral Neuropathy in Ottawa Chemotherapy Induced Peripheral Neuropathy in Winnipeg Chemotherapy Induced Peripheral Neuropathy in Quebec City Chemotherapy Induced Peripheral Neuropathy in Hamilton Chemotherapy Induced Peripheral Neuropathy in Kitchener Chemotherapy Induced Peripheral Neuropathy in London Chemotherapy Induced Peripheral Neuropathy in Halifax Chemotherapy Induced Peripheral Neuropathy in New York Chemotherapy Induced Peripheral Neuropathy in Los Angeles Chemotherapy Induced Peripheral Neuropathy in Chicago Chemotherapy Induced Peripheral Neuropathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease